Healios (TSE: 4593) is a pre-revenue regenerative-medicine biotech on the TSE Growth market (December fiscal year). The stock trades on one essentially binary question: the fate of HLCM051 (invimestrocel), its somatic stem-cell therapy, under Japan's conditional and time-limited approval pathway for ARDS (acute respiratory distress syndrome). Approval hope pulls the share price one way; years of dilutive financing pull it the other. This page summarizes the talking points, the pipeline and financing picture, and how to read the stock as of July 2026.
▶ Browse the futures markets on WEEX ・ Yahoo Finance Japan board (4593)
Healios has an active Yahoo Finance Japan board (linked above). Rather than quoting individual posts, here is the structure visible in market data and disclosures:
HLCM051 targets ARDS under the conditional and time-limited approval pathway; the company disclosed the status of that application on January 16, 2025. Critically, as of July 2026 no approval — and no rejection — has been disclosed. The January 2026 Phase 3 trial-plan submission points to a confirmatory-trial route, which implies a longer road ahead rather than an imminent decision. HLCM051 is developed for both ARDS and stroke, and the disclosed headline does not specify which indication the plan covers, so we do not over-specify it here.
Beyond HLCM051, Healios runs iPS-cell-derived programs including eNK/CAR-eNK in immuno-oncology. In October 2025 its capital alliance with Nikon was dissolved (October 14) and manufacturing was outsourced to Minaris (October 7). The company remains pre-revenue: market cap about ¥34.6 billion, price-to-book 4.58x, loss-making with no P/E and no dividend (as of July 2026). The next earnings report is due August 12, 2026.
The stock fell from a 52-week high of ¥483 (March 2, 2026) to a low of ¥234 (June 11), and traded at ¥256 on July 17 (down 4.1% that day). The March high coincided with the announcement of its inclusion in the JPX Rapid-Growth 100 index (February 13) and then faded. Bulls argue that a conditional approval would change the company's phase entirely, with the immuno-oncology pipeline as additional optionality. Bears note that no approval timeline has been disclosed, that the Phase 3 plan suggests the road is longer than hoped, and that financing keeps expanding the share count while the cash burn continues. No price target is offered here. Building a position on an assumed approval date is the specific mistake this stock invites; following the disclosures is the discipline it demands.
WEEX does not list Healios shares or any tokenized version of them. To buy the stock itself, the standard route is an account with a Japanese brokerage. What WEEX offers is global-market exposure: major crypto assets such as Bitcoin can be traded via futures (long or short, with leverage) as well as on the spot market, and tokenized products tracking major US index ETFs (QQQON/IVVON class) are also available. Tokenized equities are tracking instruments that follow the underlying share price — they are not the shares themselves. See the WEEX futures markets and the how to buy Bitcoin guide.
On the Yahoo Finance Japan board (4593) and Minkabu (4593).
No. As of July 2026 neither an approval nor a rejection has been disclosed, and the January 2026 Phase 3 plan submission suggests the process has further to run.
It is a pre-revenue biotech: approval, trial and financing disclosures move the price almost directly.
No (as of July 2026).
August 12, 2026.
This article is for information only and is not investment advice; nothing here is a recommendation to buy or sell.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

Switching crypto exchanges is routine if you do it in the right order: close and redeem first, verify both sides, withdraw safely, then restart trading deliberately. A practical checklist — including what to do when your exchange is shutting down.

With BitMart ending all trading on August 26, 2026 — and new positions already blocked — its users need a new venue now. What to look for in a replacement exchange, and how to move across without a gap in your trading.

BitMart announced an orderly wind-down on July 26, 2026: all trading ends August 26 at 01:00 UTC and the platform closes January 31, 2027. The full timeline, the recommended withdrawal deadlines, and how to move your funds out in good time.

With BitMEX closing on September 23, 2026, its derivatives traders need a new venue. What to look for in a BitMEX alternative, and how to move your perpetual-futures trading across without a gap.

BitMEX shuts down on September 23, 2026. Here is the full timeline, including the August 26 force-close, and how to withdraw your funds before the deadline to avoid the monthly fee on anything left behind.

Unipeg uPEG is an experimental on-chain asset based on Uniswap v4 hooks. We break down how it works, how it differs from NFTs and ERC-404, what the risks are, and why interest in it is growing in 2026.
























Switching crypto exchanges is routine if you do it in the right order: close and redeem first, verify both sides, withdraw safely, then restart trading deliberately. A practical checklist — including what to do when your exchange is shutting down.
With BitMart ending all trading on August 26, 2026 — and new positions already blocked — its users need a new venue now. What to look for in a replacement exchange, and how to move across without a gap in your trading.
BitMart announced an orderly wind-down on July 26, 2026: all trading ends August 26 at 01:00 UTC and the platform closes January 31, 2027. The full timeline, the recommended withdrawal deadlines, and how to move your funds out in good time.
With BitMEX closing on September 23, 2026, its derivatives traders need a new venue. What to look for in a BitMEX alternative, and how to move your perpetual-futures trading across without a gap.
BitMEX shuts down on September 23, 2026. Here is the full timeline, including the August 26 force-close, and how to withdraw your funds before the deadline to avoid the monthly fee on anything left behind.
Unipeg uPEG is an experimental on-chain asset based on Uniswap v4 hooks. We break down how it works, how it differs from NFTs and ERC-404, what the risks are, and why interest in it is growing in 2026.